Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial
Authors
Shixia Wang (ORCID: https://orcid.org/0000-0002-7748-8468)
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial
Shixia Wang, Gray Heppner, Alexander Rumyantsev, Milagros Chan et al.
Citations
1 citations
Journal
EClinicalMedicine
Topics
SARS-CoV-2 and COVID-19 Research
Field-Weighted Citation Impact (FWCI)
1.40
article
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial
Shixia Wang, Gray Heppner, Alexander Rumyantsev, Milagros Chan, Carolyn Shasha, Tracy Kemp, A. Wesley Burks, Anjuli May Jaen, Susan Hensley, Thomas P. Monath, Rodrigo DeAntonio, Maggie Lewis, Giulia Piccini, Kate Wang, Danielle S. Fisher, Alessandro Manenti, Emanuele Montomoli, Edison Alberto, Xavier Sáez‐Llorens, Lixia Wang, Rui Zhu, Amy Fix, M. Borra, Ulo Palm, Alana Wriggins, Katie Brokke
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 86
Institutions
Avans University of Applied Sciences (NL), Alliance for Multispecialty Research (United States) (US), University of Iloilo (PH), VisMederi Research (IT), St. Paul University Iloilo (PH), Altimmune (United Kingdom) (GB), Saint Paul’s Hospital Iloilo (PH)